Back to search results

CYP2C19 Genetic Testing for Stroke and TIA Patients

This study is looking at whether genetic testing for the CYP2C19 gene can help doctors choose the best antiplatelet medications for patients who have had a minor stroke or a high-risk TIA (mini-stroke). The study will test if it's practical to get your CYP2C19 genetic test results back quickly, within 6 hours of a cheek swab. You might be able to join if you are 18-89 years old, admitted to UAB hospital with a minor ischemic stroke or high-risk TIA, and are eligible for dual antiplatelet therapy. The study aims to enroll 200 participants, but its current recruitment status is unclear.

Study design
This is an interventional pilot clinical trial, meaning participants will receive a specific intervention. It plans to enroll 200 participants.
What's involved
You would have a buccal swab (cheek swab) collected. The study measures the feasibility of returning genetic test results within 6 hours of this collection.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint is measured at 6 hours from buccal swab collection.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06943586

Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing

Recruiting
NAAges 18–89InterventionalHealth services
University of Alabama at Birmingham
~200 participants
Updated 2026-04-23 on ClinicalTrials.gov
What's tested:CYP2C19 Genotype Guided DAPT (dual antiplatelet therapy)

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Stroke participant feasibility of return of CYP2C19 genetic testing results
Measured over 6 hours from buccal swab collection

Conditions

Stroke
Transient Ischemic Attack (TIA)

Explore related trials

StrokeTransient Ischemic Attack

Where it's being run

1 sites across 1 states
Alabama1

Study leadership

  • Ekaterina Bakradze, MD · PRINCIPAL_INVESTIGATOR · University of Alabama at Birmingham

Who to contact

Ekaterina Bakradze, MD
[email protected]
205-975-8569
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients 18-89 years of age
admitted to University of Alabama at Birmingham (UAB) main hospital with symptoms or signs of minor ischemic stroke, or high risk TIA
eligible to receive dual antiplatelet load (presented to the hospital within 66 hours of last known well)

Exclusion

diagnosis of atrial fibrillation, valvular heart disease, index stroke due to known hypercoagulability (subset of other determined etiology) or large vessel disease (culprit vessel stenosis of ≥50%)
prescribed anticoagulation prior to stroke
treated with intravenous thrombolysis
treated with mechanical thrombectomy
missing NIH Stroke Scale score

What this trial measures

  • Stroke participant feasibility of return of CYP2C19 genetic testing results6 hours from buccal swab collection

    This outcome is to determine the feasibility of receiving CYP2C19 genetic testing results (strata-normal vs. loss-of-function allele) on minor ischemic stroke and high risk TIA inpatients within a 6-hour window to determine drug metabolization for antiplatelet effect to guide standard of care treatment. Inpatients that have been admitted to the hospital, within 66 hours of last known well time, will have buccal swabs collected during hospitalization for the CYP2C19 genetic testing. Results must be received within 6 hours to effectively randomize subjects.